Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

BI 1265162

Phase Two

Phase Two

Therapeutic Approach

Mucociliary Clearance

BI 1265162 is a compound designed to block the function of the sodium (Na+) channel found in the lungs.  These channels move sodium and water away from the airway surface. Blocking these channels may help maintain fluid within the airways to improve mucus clearance.

Status

A phase 2 study to test the safety and effectiveness of BI 1265162 is planned.

Sponsor

This program is sponsored by Boehringer Ingelheim. It is being conducted within the CFF's Therapeutics Development Network.



Contact us about BI 1265162 >